JP4953570B2 - アジュバントウィルス粒子 - Google Patents
アジュバントウィルス粒子 Download PDFInfo
- Publication number
- JP4953570B2 JP4953570B2 JP2004518318A JP2004518318A JP4953570B2 JP 4953570 B2 JP4953570 B2 JP 4953570B2 JP 2004518318 A JP2004518318 A JP 2004518318A JP 2004518318 A JP2004518318 A JP 2004518318A JP 4953570 B2 JP4953570 B2 JP 4953570B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- papmv
- vlp
- composition according
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000700605 Viruses Species 0.000 title claims description 51
- 239000002245 particle Substances 0.000 title claims description 48
- 239000002671 adjuvant Substances 0.000 title claims description 39
- 241000709995 Papaya mosaic virus Species 0.000 claims description 78
- 239000000427 antigen Substances 0.000 claims description 72
- 108091007433 antigens Proteins 0.000 claims description 72
- 102000036639 antigens Human genes 0.000 claims description 72
- 230000028993 immune response Effects 0.000 claims description 53
- 230000002163 immunogen Effects 0.000 claims description 48
- 229960005486 vaccine Drugs 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 101710132601 Capsid protein Proteins 0.000 claims description 12
- 101710094648 Coat protein Proteins 0.000 claims description 12
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 12
- 101710125418 Major capsid protein Proteins 0.000 claims description 12
- 101710141454 Nucleoprotein Proteins 0.000 claims description 12
- 101710083689 Probable capsid protein Proteins 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 230000007774 longterm Effects 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 230000015654 memory Effects 0.000 claims description 5
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 108700030444 papaya mosiac virus coat Proteins 0.000 claims 15
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- 230000003612 virological effect Effects 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 210000000987 immune system Anatomy 0.000 description 13
- 239000013256 coordination polymer Substances 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108090000565 Capsid Proteins Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 241001112090 Pseudovirus Species 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 108010013381 Porins Proteins 0.000 description 5
- 102000017033 Porins Human genes 0.000 description 5
- 208000037386 Typhoid Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000002434 immunopotentiative effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 201000008297 typhoid fever Diseases 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000091 immunopotentiator Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000710007 Potexvirus Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000723655 Cowpea mosaic virus Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000709992 Potato virus X Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 241000287433 Turdus Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000724328 Alfalfa mosaic virus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 101150083464 CP gene Proteins 0.000 description 1
- 241000219173 Carica Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700008783 Hepatitis C virus E1 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/26011—Flexiviridae
- C12N2770/26023—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39365902P | 2002-07-05 | 2002-07-05 | |
| US60/393,659 | 2002-07-05 | ||
| PCT/CA2003/000985 WO2004004761A2 (en) | 2002-07-05 | 2003-06-30 | Adjuvant viral particle |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006504644A JP2006504644A (ja) | 2006-02-09 |
| JP2006504644A5 JP2006504644A5 (enExample) | 2006-08-31 |
| JP4953570B2 true JP4953570B2 (ja) | 2012-06-13 |
Family
ID=30115621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004518318A Expired - Fee Related JP4953570B2 (ja) | 2002-07-05 | 2003-06-30 | アジュバントウィルス粒子 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7641896B2 (enExample) |
| EP (2) | EP1523329B1 (enExample) |
| JP (1) | JP4953570B2 (enExample) |
| KR (1) | KR20050044886A (enExample) |
| CN (1) | CN1665528B (enExample) |
| AU (1) | AU2003281246A1 (enExample) |
| BR (1) | BR0312474A (enExample) |
| CA (1) | CA2434000C (enExample) |
| DK (1) | DK1523329T3 (enExample) |
| ES (1) | ES2431963T3 (enExample) |
| MX (1) | MXPA05000287A (enExample) |
| NO (1) | NO20050396L (enExample) |
| PT (1) | PT1523329E (enExample) |
| WO (1) | WO2004004761A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05000287A (es) * | 2002-07-05 | 2005-09-08 | Leclerc Denis | Particula viral adyuvante. |
| US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| NZ554387A (en) * | 2004-09-21 | 2009-09-25 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| NZ554386A (en) | 2004-10-25 | 2009-12-24 | Cytos Biotechnology Ag | Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof |
| KR100688522B1 (ko) * | 2005-01-18 | 2007-03-02 | 삼성전자주식회사 | 영상데이터 압축기 및 압축방법 |
| CA2608515A1 (en) | 2005-06-01 | 2007-05-10 | Dow Global Technolgies Inc. | Production of multivalent virus like particles |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| US20100111996A1 (en) * | 2006-11-15 | 2010-05-06 | Denis Leclerc | Papaya Mosaic Virus-Based Vaccines for Influenza |
| WO2008058369A1 (en) | 2006-11-15 | 2008-05-22 | Folia Biotech Inc. | Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof |
| EP2082042A4 (en) * | 2007-01-26 | 2010-08-18 | Folia Biotech Inc | VACCINE VACCINE FROM PAPAYA MOSAIC AGAINST SALMONELLA TYPHI AND OTHER ENTEROBACTERIAL PATHOGENS |
| AU2008279584A1 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
| JP2010538619A (ja) * | 2007-09-11 | 2010-12-16 | ユニベルシテ ラヴァル | Ｍａｌｖａモザイクウイルスおよびウイルス様粒子およびこれらの使用 |
| WO2010003219A1 (en) * | 2008-06-17 | 2010-01-14 | Universite Laval | Compositions comprising salmonella porins and uses thereof as adjuvants and vaccines |
| WO2010012069A1 (en) * | 2008-07-30 | 2010-02-04 | Folio Biotech Inc. | Multivalent vaccines based on papaya mosaic virus and uses thereof |
| CA2763795A1 (en) * | 2010-10-14 | 2012-03-20 | Folia Biotech Inc. | Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof |
| WO2012078069A1 (en) * | 2010-12-09 | 2012-06-14 | Iosif Grigorievich Atabekov | Spherical nano- and microparticles derived from plant viruses for the display of foreign proteins or epitopes |
| DK2707480T3 (da) * | 2011-05-13 | 2017-11-13 | Folia Biotech Inc | Viruslignende partikler og fremgangsmåde til fremstilling heraf |
| PT2717910T (pt) | 2011-06-09 | 2019-05-22 | Biomay Ag | Proteínas de fusão transportadoras de péptido como vacinas para alergia |
| WO2013149334A1 (en) * | 2012-04-02 | 2013-10-10 | Folia Biotech Inc. | Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines |
| WO2015039255A1 (en) * | 2013-09-19 | 2015-03-26 | Folia Biotech Inc. | Papaya mosaic virus and virus-like particles in cancer therapy |
| WO2016176558A1 (en) * | 2015-04-30 | 2016-11-03 | The Regents Of The University Of California | Adjuvant particles comprising adenosine receptor antagonists |
| WO2021198963A1 (en) * | 2020-03-31 | 2021-10-07 | Mediphage Bioceuticals, Inc. | Vectors for producing virus-like particles and uses thereof |
| AU2022208435A1 (en) | 2021-01-18 | 2023-08-10 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL79880A0 (en) | 1985-08-29 | 1986-11-30 | Inst Medical W & E Hall | Recombinant virus |
| US5977438A (en) * | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
| DE4006630A1 (de) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung |
| DE69128898T2 (de) * | 1990-08-15 | 1998-05-28 | Therion Biolog Corp | Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel |
| US5443969A (en) * | 1992-10-29 | 1995-08-22 | Rutgers University | RNA packaging system |
| GB9414118D0 (en) * | 1994-07-13 | 1994-08-31 | Axis Genetics Ltd | Modified plant viruses as vectors of heterologous peptides |
| CA2202761A1 (en) | 1994-10-18 | 1996-04-25 | Sean Nicholas Chapman | Method of producing a chimeric protein |
| GB9607899D0 (en) | 1996-04-17 | 1996-06-19 | Scottish Crop Research Inst | Virus-like particle |
| US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
| AU750702B2 (en) * | 1997-05-01 | 2002-07-25 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| DE19752855C2 (de) | 1997-11-28 | 2003-04-03 | Bundesrepublik Deutschland Let | Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer |
| GB9806666D0 (en) | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| WO2000006717A2 (en) | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| FR2786773B1 (fr) | 1998-12-03 | 2002-03-08 | Univ Paris Curie | Proteines d'enveloppe, methodes et utilisations |
| DK1135408T3 (da) * | 1998-12-04 | 2012-01-23 | Biogen Idec Inc | HBV-kerneantigenpartikler med multipelle immunogene komponenter, som er bundne via peptidligander |
| DE19904800C1 (de) | 1999-02-05 | 2001-02-08 | Eberhard Hildt | Partikel zur Gentherapie |
| GB9921337D0 (en) * | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
| GB9924352D0 (en) | 1999-10-14 | 1999-12-15 | Hellendoorn Koen | Methods,compositions and applications relating to the generation of novel plant viral particles |
| GB9924351D0 (en) * | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
| US6730306B1 (en) | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
| AUPQ661600A0 (en) | 2000-03-31 | 2000-05-04 | Macfarlane Burnet Centre For Medical Research Limited, The | A nucleic acid construct and methods related thereto |
| IT1317046B1 (it) | 2000-06-16 | 2003-05-26 | Ist Superiore Sanita | Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni |
| AU2001270164A1 (en) | 2000-06-26 | 2002-01-08 | The United States Of America As Represented By The Secretary Of Agriculture | Production of vaccines using transgenic plants |
| ATE418997T1 (de) | 2000-07-06 | 2009-01-15 | Univ Georgetown | Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen |
| GB0028319D0 (en) * | 2000-11-20 | 2001-01-03 | Univ Southampton | Materials and methods relating to fusion proteins for inducing an immune response |
| ITRM20010332A1 (it) * | 2001-06-11 | 2002-12-11 | Ist Superiore Sanita | Vaccini a subunita' e procedimenti per la loro produzione. |
| US8101189B2 (en) * | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| MXPA05000287A (es) * | 2002-07-05 | 2005-09-08 | Leclerc Denis | Particula viral adyuvante. |
-
2003
- 2003-06-30 MX MXPA05000287A patent/MXPA05000287A/es active IP Right Grant
- 2003-06-30 EP EP03739913.6A patent/EP1523329B1/en not_active Expired - Lifetime
- 2003-06-30 BR BR0312474-6A patent/BR0312474A/pt not_active Application Discontinuation
- 2003-06-30 KR KR1020057000114A patent/KR20050044886A/ko not_active Withdrawn
- 2003-06-30 EP EP10179379A patent/EP2272525A3/en not_active Withdrawn
- 2003-06-30 DK DK03739913.6T patent/DK1523329T3/da active
- 2003-06-30 CA CA2434000A patent/CA2434000C/en not_active Expired - Fee Related
- 2003-06-30 AU AU2003281246A patent/AU2003281246A1/en not_active Abandoned
- 2003-06-30 ES ES03739913T patent/ES2431963T3/es not_active Expired - Lifetime
- 2003-06-30 PT PT37399136T patent/PT1523329E/pt unknown
- 2003-06-30 CN CN03815935XA patent/CN1665528B/zh not_active Expired - Fee Related
- 2003-06-30 WO PCT/CA2003/000985 patent/WO2004004761A2/en not_active Ceased
- 2003-06-30 JP JP2004518318A patent/JP4953570B2/ja not_active Expired - Fee Related
- 2003-07-01 US US10/609,417 patent/US7641896B2/en not_active Expired - Fee Related
-
2005
- 2005-01-25 NO NO20050396A patent/NO20050396L/no not_active Application Discontinuation
-
2009
- 2009-04-03 US US12/384,476 patent/US8282940B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7641896B2 (en) | 2010-01-05 |
| WO2004004761A2 (en) | 2004-01-15 |
| HK1075214A1 (en) | 2005-12-09 |
| PT1523329E (pt) | 2013-10-08 |
| US20090280145A1 (en) | 2009-11-12 |
| CN1665528B (zh) | 2013-05-15 |
| WO2004004761A3 (en) | 2004-05-06 |
| ES2431963T3 (es) | 2013-11-28 |
| EP1523329B1 (en) | 2013-07-24 |
| DK1523329T3 (da) | 2013-10-14 |
| US20050048082A1 (en) | 2005-03-03 |
| US8282940B2 (en) | 2012-10-09 |
| NO20050396L (no) | 2005-01-25 |
| BR0312474A (pt) | 2005-04-26 |
| MXPA05000287A (es) | 2005-09-08 |
| EP2272525A3 (en) | 2011-11-16 |
| CA2434000C (en) | 2012-07-17 |
| JP2006504644A (ja) | 2006-02-09 |
| CN1665528A (zh) | 2005-09-07 |
| AU2003281246A1 (en) | 2004-01-23 |
| KR20050044886A (ko) | 2005-05-13 |
| EP1523329A2 (en) | 2005-04-20 |
| CA2434000A1 (en) | 2004-01-05 |
| EP2272525A2 (en) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8282940B2 (en) | Adjuvant viral particle | |
| EP1223977B1 (en) | Modified plant viruses and methods of use thereof | |
| ES2139879T5 (es) | Adyuvante de la mucosa no toxico. | |
| US9339535B2 (en) | Vaccines and immunopotentiating compositions and methods for making and using them | |
| JP2010516713A (ja) | 腸チフス菌および他の腸内細菌病原体に対するパパイアモザイクウィルスベースのワクチン | |
| JP2006504644A5 (enExample) | ||
| Smith et al. | Display of peptides on the surface of tobacco mosaic virus particles | |
| Narayanan et al. | Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy | |
| Francis | Peptide vaccines for viral diseases | |
| EP0597838A1 (en) | Vaccine compositions | |
| HK1151730A (en) | Adjuvant viral particle | |
| HK1075214B (en) | Adjuvant viral particle | |
| Astori et al. | Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic | |
| Roitt | Basic concepts and new aspects of vaccine development | |
| WO2008015309A1 (es) | Construcción peptídica dendrimérica para la prevención de la fiebre aftosa en animales. | |
| Domansky | Transgenic plants as edible vaccines–reality and future prospects | |
| Kit | See also: Biologicals (/content/biologicals/083000); Immunity (/content/immunity/338100); Immunology (/content | |
| Falzarano | Edible vaccines: immunological response to hepatitis B virus nucleocapsid derived from transgenic plants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060712 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090811 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091105 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091201 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100212 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100709 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110415 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120214 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120313 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150323 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |